Targeted Protein Degradation Oncology (PROTAC) Market Global Report 2026

The targeted protein degradation oncology (PROTAC) market size has grown exponentially in recent years. It will grow from $1.3 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 26.0%. The growth in the historic period can be attributed to rising cancer prevalence globally driving demand for novel therapeutics, limitations of traditional small molecule inhibitors in oncology treatment, growth in targeted cancer therapy research and clinical trials, increasing investment in biotechnology and pharmaceutical r&d, expansion of precision medicine approaches in oncology care.

The targeted protein degradation oncology (PROTAC) market size is expected to see exponential growth in the next few years. It will grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 26.2%. The growth in the forecast period can be attributed to increasing adoption of next generation protein degradation platforms in oncology pipelines, rising demand for therapies targeting undruggable cancer proteins, expansion of biomarker driven personalized cancer treatment approaches, growing clinical validation of PROTAC based therapeutics, increasing pharmaceutical partnerships and biotech innovation funding. Major trends in the forecast period include ai driven protein degradation target discovery platforms for oncology drug design optimization, precision oncology expansion through tumor specific proteolysis targeting chimera development, next generation molecular glue degraders for overcoming cancer drug resistance mechanisms, advanced lysosome targeting chimera systems for selective cancer cell protein elimination, hybrid multi modal protein degradation therapies combining PROTAC and autophagy pathways.

The increasing incidence of cancer is expected to drive the growth of the targeted protein degradation oncology (PROTAC) market in the coming years. Cancer incidence refers to the occurrence rate of newly diagnosed cancer cases within a particular population during a specified period. The growing prevalence of cancer is primarily attributed to an aging population, as older individuals experience prolonged exposure to carcinogenic factors and a gradual decline in cellular repair processes. The increasing cancer burden is fueling the demand for innovative and highly targeted therapeutic approaches, as traditional treatments often struggle to effectively address undruggable oncoproteins, creating the need for selective degradation technologies such as targeted protein degradation oncology (PROTAC). For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, global cancer cases were projected to exceed 35 million new cases by 2050, reflecting a 77% rise from the estimated 20 million cases reported in 2022. Therefore, the rising incidence of cancer is contributing to the expansion of the targeted protein degradation oncology (PROTAC) market.

Leading companies operating in the targeted protein degradation oncology (PROTAC) market are concentrating on the development of advanced solutions, including oral PROTAC protein degraders, to improve therapeutic effectiveness, enhance patient convenience, and address previously undruggable cancer-driving proteins. Oral PROTAC protein degraders are orally delivered therapeutic agents that selectively trigger the breakdown of disease-associated proteins by utilizing the body’s natural protein degradation pathways. For instance, in February 2024, Arvinas Inc., a US-based clinical-stage biotechnology company, collaborated with Pfizer Inc., a US-based biopharmaceutical and biotechnology corporation, to announce that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the evaluation of vepdegestrant (ARV-471). This designation supports the accelerated development and regulatory review of a novel targeted protein degrader for treating ER+/HER2- locally advanced or metastatic breast cancer with significant unmet medical needs. Vepdegestrant (ARV-471) is a PROTAC protein degrader developed to selectively target and eliminate the estrogen receptor (ER), rather than only blocking its function.

In November 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired the ORM-6151 program from Orum Therapeutics for an undisclosed amount. Through this acquisition, Bristol Myers Squibb aims to strengthen its oncology pipeline and enhance its protein degradation capabilities by advancing a first-in-class anti-CD33 antibody-enabled GSPT1 degrader for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Orum Therapeutics is a US-based clinical-stage biotechnology company focused on developing dual-precision targeted protein degradation (TPD²) and targeted protein stabilization (TPS²) technologies for cancer therapies.

Major companies operating in the targeted protein degradation oncology (protac) market report are AbbVie Inc., Amgen Inc., Amphista Therapeutics Limited, Arvinas Inc., AstraZeneca plc, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, C4 Therapeutics Inc., Dialectic Therapeutics Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Foghorn Therapeutics Inc., Gilead Sciences Inc., GSK plc, Johnson & Johnson, Kymera Therapeutics Inc., Merck & Co. Inc., Monte Rosa Therapeutics Inc., Novartis AG, Nurix Therapeutics Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.

North America was the dominating region in the targeted protein degradation oncology (PROTAC) market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the targeted protein degradation oncology (PROTAC) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the targeted protein degradation oncology (PROTAC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.